Skip to main content

Table 3 Relative expression levels of KRAS (A) and HRAS (B) mRNA in tissue of NSCLC patients, compared to clinicopathological and demographical features

From: Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings

 

Relative KRAS expression level in tissue

 

N

Median

Minimum

Maximum

p-value

A

All cases

35

0.8917

0.0631

12.9178

 

Cigarette

No

13

0.7730

0.0631

7.0357

1.0000

Yes

22

0.9600

0.0941

12.9178

Sexr

Women

7

0.7730

0.0941

8.2563

0.8528

Men

28

0.9586

0.0631

12.9178

Age

<= 67

18

0.3768

0.0941

3.5158

0.0361

>  67

17

1.2411

0.0631

12.9178

Histological type of cancer

Squamous

21

0.8917

0.0941

12.9178

0.5333

Glandular

14

0.8652

0.0631

7.0357

TNM stage

IA1 and/or IA2 and/or IB

16

0.9589

0.0631

12.9178

0.9868

II A and/or II B and/or IIIA

19

0.7534

0.1109

8.2563

Grade of histological malignancy [G]

G1 and/or G2

27

0.9575

0.0631

12.9178

0.5169

G3

8

0.5918

0.1109

6.4671

Chemotherapy

No

22

0.8045

0.0631

12.9178

0.1887

Yes

13

0.9597

0.2825

7.0357

B

All cases

35

0.9779

0.0544

24.1938

 

Cigarette

No

13

0.9779

0.0737

11.5889

0.7491

Yes

22

0.8728

0.0544

24.1938

Sex

Women

7

0.2131

0.0737

6.7824

0.3325

Men

28

1.0848

0.0544

24.1938

Age

<= 67

18

0.3621

0.0544

5.3788

0.0892

>  67

17

1.2699

0.0653

24.1938

Histological type of cancer

Squamous

21

0.4161

0.0544

24.1938

0.0489

Glandular

14

1.6400

0.0797

11.5889

TNM stage

IA1 and/or IA2 and/or IB

16

0.6167

0.0737

24.1938

0.6311

II A and/or II B and/or IIIA

19

1.0854

0.0544

11.5889

Grade of histological malignancy [G]

G1 and/or G2

27

0.6614

0.0737

24.1938

0.7683

G3

8

1.2824

0.0544

11.5889

Chemotherapy

No

22

0.4941

0.0544

24.1938

0.0978

Yes

13

1.3379

0.1702

11.5889